ABSI vs. OABI, MXCT, HARP, TCRX, TNYA, ORIC, NOTV, PNTG, EDIT, and SIGA
Should you be buying Absci stock or one of its competitors? The main competitors of Absci include OmniAb (OABI), MaxCyte (MXCT), Harpoon Therapeutics (HARP), TScan Therapeutics (TCRX), Tenaya Therapeutics (TNYA), ORIC Pharmaceuticals (ORIC), Inotiv (NOTV), The Pennant Group (PNTG), Editas Medicine (EDIT), and SIGA Technologies (SIGA). These companies are all part of the "medical" sector.
OmniAb (NASDAQ:OABI) and Absci (NASDAQ:ABSI) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, dividends, analyst recommendations, risk, media sentiment, community ranking and valuation.
In the previous week, OmniAb had 15 more articles in the media than Absci. MarketBeat recorded 32 mentions for OmniAb and 17 mentions for Absci. Absci's average media sentiment score of 0.61 beat OmniAb's score of -0.09 indicating that OmniAb is being referred to more favorably in the media.
OmniAb has higher revenue and earnings than Absci. OmniAb is trading at a lower price-to-earnings ratio than Absci, indicating that it is currently the more affordable of the two stocks.
OmniAb currently has a consensus price target of $9.20, indicating a potential upside of 68.81%. Absci has a consensus price target of $9.25, indicating a potential upside of 62.85%. Given Absci's higher probable upside, analysts clearly believe OmniAb is more favorable than Absci.
OmniAb has a beta of -0.16, indicating that its stock price is 116% less volatile than the S&P 500. Comparatively, Absci has a beta of 2.35, indicating that its stock price is 135% more volatile than the S&P 500.
Absci received 4 more outperform votes than OmniAb when rated by MarketBeat users. However, 100.00% of users gave OmniAb an outperform vote while only 52.50% of users gave Absci an outperform vote.
72.1% of OmniAb shares are owned by institutional investors. Comparatively, 52.1% of Absci shares are owned by institutional investors. 7.0% of OmniAb shares are owned by insiders. Comparatively, 11.6% of Absci shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
OmniAb has a net margin of -148.16% compared to OmniAb's net margin of -1,933.65%. Absci's return on equity of -15.41% beat OmniAb's return on equity.
Summary
OmniAb beats Absci on 12 of the 17 factors compared between the two stocks.
Get Absci News Delivered to You Automatically
Sign up to receive the latest news and ratings for ABSI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ABSI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Related Companies and Tools